Gabapentin is NOT a recommended treatment for akathisia
Based on the highest quality guideline evidence, gabapentin should not be used for akathisia. The 2020 American Psychiatric Association guidelines for schizophrenia explicitly recommend only four treatment options for antipsychotic-induced akathisia: lowering the antipsychotic dose, switching to another antipsychotic, adding a benzodiazepine, or adding a beta-adrenergic blocking agent 1. Gabapentin is notably absent from these evidence-based recommendations.
Why Gabapentin Is Not Recommended
The APA guideline provides a clear, algorithmic approach to akathisia management with a 2C strength recommendation (suggesting moderate confidence in the evidence). The four recommended options are:
- Lower the antipsychotic dose - First-line approach when clinically feasible
- Switch to another antipsychotic - Particularly to one with lower akathisia risk
- Add a benzodiazepine - Evidence-supported pharmacologic intervention
- Add a beta-blocker - Evidence-supported pharmacologic intervention
The Research Evidence on Gabapentin
While several small studies suggest gabapentin or its prodrug gabapentin enacarbil might help akathisia 2, 3, 4, 5, these are limited to case reports and a single open-label pilot study with only 9 patients 2. The most recent and comprehensive network meta-analysis from 2024 evaluated 15 randomized controlled trials involving 492 participants and found that mirtazapine, biperiden, vitamin B6, trazodone, mianserin, and propranolol were associated with efficacy for akathisia 6. Gabapentin was not included in this analysis, indicating insufficient high-quality evidence.
Another 2024 network meta-analysis similarly found that benzodiazepines, beta-blockers, and NaSSA (like mirtazapine) demonstrated significant efficacy, while anticonvulsants (the class including gabapentin) did not show significant differences from placebo 7.
Evidence-Based Treatment Hierarchy
For pharmacologic management of akathisia, use this approach:
- First choice: Propranolol (20-80 mg/day) or mirtazapine (15 mg/day) - strongest evidence base 6
- Second choice: Benzodiazepines (e.g., clonazepam) - guideline-recommended 1
- Alternative options: Vitamin B6 (600-1200 mg/day), biperiden (6 mg/day), trazodone (50 mg/day) 6
Important Caveats
The FDA labeling for gabapentin does not list akathisia as an approved indication 8. In fact, one case report describes akathisia potentially induced by a gabapentin-related compound (mirogabalin) 9, raising theoretical safety concerns.
The review article using the "B-CALM" mnemonic (Beta-blockers, Clonazepam, Anticholinergics, cLonidine, Mirtazapine) explicitly states that while gabapentin has been examined, "the current evidence is insufficient" and concludes that "current evidence best supports the use of propranolol and mirtazapine" 10.
Bottom line: Stick with guideline-recommended treatments (beta-blockers or benzodiazepines) or the evidence-based alternatives (mirtazapine, vitamin B6) rather than using gabapentin, which lacks sufficient supporting evidence and guideline endorsement for akathisia management.